{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:42:02Z","timestamp":1774406522476,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T00:00:00Z","timestamp":1393891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s11845-014-1084-5","type":"journal-article","created":{"date-parts":[[2014,3,3]],"date-time":"2014-03-03T19:29:54Z","timestamp":1393874994000},"page":"183-188","source":"Crossref","is-referenced-by-count":27,"title":["Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy"],"prefix":"10.1007","volume":"184","author":[{"given":"A.","family":"Mukhopadhyay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Kanti Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gharami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. K.","family":"Bose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,4]]},"reference":[{"key":"1084_CR1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V100.2.435","volume":"100","author":"RM Braziel","year":"2002","unstructured":"Braziel RM, Launder TM, Druker BJ et al (2002) Hematopathologic and cytogenetic findings in imatinib mesylate treated CML patients: 14\u00a0months\u2019 experience. Blood 100:435\u2013441","journal-title":"Blood"},{"issue":"23","key":"1084_CR2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J\u00a0Med 355(23):2408\u20132417","journal-title":"N Engl J\u00a0Med"},{"key":"1084_CR3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561\u2013566. doi: 10.1038\/nm0596-561","journal-title":"Nat Med"},{"issue":"9","key":"1084_CR4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","volume":"6","author":"A Quintas-Cardiama","year":"2009","unstructured":"Quintas-Cardiama A, Kantarjian H, Cortes J (2009) Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 6(9):535\u2013543. doi: 10.1038\/nrclinonc.2009.112","journal-title":"Nat Rev Clin Oncol"},{"key":"1084_CR5","unstructured":"National Cancer Institute Washington DC: Annual cancer statistics review. USA Department of Health and Human Services. www.cancer.gov"},{"key":"1084_CR6","first-page":"87","volume":"178","author":"MF Fey","year":"2008","unstructured":"Fey MF, Surbek D (2008) Leukaemia and pregnancy. Recent Results Cancer Res 178:87\u2013110","journal-title":"Recent Results Cancer Res"},{"issue":"2 Suppl 2","key":"1084_CR7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/shem.2003.50038","volume":"40","author":"ML Hensley","year":"2003","unstructured":"Hensley ML, Ford JM (2003) Imatinib treatment: specific issues related to safety, fertility and pregnancy. Semin Hematol 40(2 Suppl 2):21\u201325","journal-title":"Semin Hematol"},{"issue":"4","key":"1084_CR8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3816\/CLM.2009.n.064","volume":"9","author":"S Cole","year":"2009","unstructured":"Cole S, Kantarjian H, Ault P, Cortes JE (2009) Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of literature. Clin Lymphoma Myeloma 9(4):324\u2013327","journal-title":"Clin Lymphoma Myeloma"},{"issue":"12","key":"1084_CR9","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P et al (2008) The effects of imatinib on pregnancy outcome. Blood 111(12):5505\u20135508","journal-title":"Blood"},{"issue":"3","key":"1084_CR10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderal","year":"1999","unstructured":"Faderal S, Talpaz Estrov E (1999) The biology of chronic myeloid leukemia. N Engl J Med 341(3):164\u2013172","journal-title":"N Engl J Med"},{"issue":"4","key":"1084_CR11","first-page":"215","volume":"34","author":"R Ali","year":"2004","unstructured":"Ali R, Ozkalemkas F, Ozkocaman V et al (2004) Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with Leukapheresis during pregnancy: a case report and review of the literature. J Clin Oncol 34(4):215\u2013217","journal-title":"J Clin Oncol"},{"key":"1084_CR12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12288-011-0108-9","volume":"28","author":"A Mukhopadhyay","year":"2012","unstructured":"Mukhopadhyay A, Dasgupta S, Mukhopadhyay S et al (2012) Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: an experience from eastern India. Indian J Haematol Blood Transfus 28:82\u201388","journal-title":"Indian J Haematol Blood Transfus"},{"issue":"1","key":"1084_CR13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","volume":"101","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, Cortes JE, O\u2019Brien S (2003) Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 101(1):97\u2013100","journal-title":"Blood"},{"key":"1084_CR14","first-page":"1","volume":"28","author":"LA Jacob","year":"2007","unstructured":"Jacob LA, Bapsy PP, BabuK Govind et al (2007) Lokanatha imatinib mesylate in newly diagnosed patients of chronic myeloid leukemia. Indian J Med Paediatr Oncol 28:1","journal-title":"Indian J Med Paediatr Oncol"},{"key":"1084_CR15","first-page":"291","volume":"53","author":"C Deshmukh","year":"2005","unstructured":"Deshmukh C, Saikia T, Bakshi A et al (2005) Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study. J Assoc Phy India 53:291\u2013295","journal-title":"J Assoc Phy India"},{"issue":"47","key":"1084_CR16","first-page":"3","volume":"3","author":"W Guoqing","year":"2010","unstructured":"Guoqing W, Shamudheen R, Delong L (2010) First line treatment for chronic myeloid leukemia: dasatinib, nilotinib or imatinib. J Hematol Oncol 3(47):3\u201310","journal-title":"J Hematol Oncol"},{"key":"1084_CR17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.jp.7211665","volume":"27","author":"MA Russell","year":"2007","unstructured":"Russell MA, Carpenter MW, Akhtar MS et al (2007) Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 27:241\u2013243","journal-title":"J Perinatol"},{"issue":"23","key":"1084_CR18","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1200\/JCO.2006.06.9310","volume":"24","author":"R Ali","year":"2006","unstructured":"Ali R, Ozkalemkas F, Ozcelik T et al (2006) Imatinib and pregnancy. J Clin Oncol 24(23):3812\u20133813","journal-title":"J Clin Oncol"},{"issue":"2","key":"1084_CR19","first-page":"1528","volume":"7","author":"P Ault","year":"2010","unstructured":"Ault P, Cortes J (2010) Planned pregnancy for a patient with chronic myeloid leukemia. Inter J Oncol 7(2):1528\u20138331","journal-title":"Inter J Oncol"},{"key":"1084_CR20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/oxfordjournals.aje.a114982","volume":"128","author":"HA Risch","year":"1988","unstructured":"Risch HA, Weiss NS, Clarke EA et al (1988) Miller AB. Risk factors for spontaneous abortion and its recurrence. Am J Epidemiol 128:420\u2013430","journal-title":"Am J Epidemiol"},{"key":"1084_CR21","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","volume":"24","author":"P Ault","year":"2006","unstructured":"Ault P, Kantarjian H, O\u2019Brien S et al (2006) Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24:1204\u20131208","journal-title":"J Clin Oncol"},{"issue":"3","key":"1084_CR22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2011.09.025","volume":"36","author":"Beate Schultheis","year":"2012","unstructured":"Schultheis Beate, Nijmeijer BA, Yin H et al (2012) Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res 36(3):271\u2013274","journal-title":"Leuk Res"},{"key":"1084_CR23","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","volume":"351","author":"T Seshadri","year":"2004","unstructured":"Seshadri T, Seymour JF, McArthur GA (2004) Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 351:2134\u20132135","journal-title":"N Engl J Med"},{"issue":"4","key":"1084_CR24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.reprotox.2010.12.056","volume":"31","author":"C Heim","year":"2011","unstructured":"Heim C, Minniear K, Dann CT (2011) Imatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal. Reprod Toxicol 31(4):454\u2013463","journal-title":"Reprod Toxicol"},{"key":"1084_CR25","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2010-04-280206","volume":"116","author":"A Kuwabara","year":"2010","unstructured":"Kuwabara A, Babb A, Ibrahim A et al (2010) Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116:1014\u20131016","journal-title":"Blood"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-014-1084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11845-014-1084-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-014-1084-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T23:49:35Z","timestamp":1565221775000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11845-014-1084-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,4]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["1084"],"URL":"https:\/\/doi.org\/10.1007\/s11845-014-1084-5","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,4]]}}}